Validation of the Molecular International Prognostic Scoring System in patients with myelodysplastic syndromes.
作者信息
Kewan Tariq, Bahaj Waled, Durmaz Arda, Aly Mai, Ogbue Olisaemeka D, Carraway Hetty E, Sekeres Mikkael A, Visconte Valeria, Gurnari Carmelo, Maciejewski Jaroslaw P
机构信息
Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
Department of Hematology and Oncology, Yale University, New Haven, CT.
出版信息
Blood. 2023 Apr 6;141(14):1768-1772. doi: 10.1182/blood.2022018896.
Abstract
摘要
相似文献
1
Validation of the Molecular International Prognostic Scoring System in patients with myelodysplastic syndromes.分子国际预后评分系统在骨髓增生异常综合征患者中的验证
Blood. 2023 Apr 6;141(14):1768-1772. doi: 10.1182/blood.2022018896.
2
Prognostic molecular markers in myelodysplastic syndromes.骨髓增生异常综合征的预后分子标志物。
Expert Rev Hematol. 2009 Oct;2(5):563-75. doi: 10.1586/ehm.09.44.
3
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).WHO 分类为基础的预后评分系统（WPSS）在骨髓增生异常综合征中的验证，并与修订后的国际预后评分系统（IPSS-R）进行比较。这是骨髓增生异常综合征预后国际工作组（IWG-PM）的一项研究。
Leukemia. 2015 Jul;29(7):1502-13. doi: 10.1038/leu.2015.55. Epub 2015 Feb 27.
4
Validation of Molecular International Prognostic Scoring System (IPSS-M) in myelodysplastic/myeloproliferative neoplasms, not otherwise specified (MDS/MPN-NOS).分子国际预后评分系统（IPSS-M）在未另行指定的骨髓增生异常/骨髓增殖性肿瘤（MDS/MPN-NOS）中的验证
Leuk Res. 2023 Aug;131:107340. doi: 10.1016/j.leukres.2023.107340. Epub 2023 Jun 20.
5
Clinical and genetic predictors of prognosis in myelodysplastic syndromes.骨髓增生异常综合征预后的临床和遗传预测指标
Haematologica. 2014 Jun;99(6):956-64. doi: 10.3324/haematol.2013.085217.
6
Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry.修订后的国际预后评分系统（IPSS-R）在低危骨髓增生异常综合征患者中的验证：来自欧洲白血病网骨髓增生异常综合征（EUMDS）前瞻性注册研究的报告
Br J Haematol. 2015 Aug;170(3):372-83. doi: 10.1111/bjh.13450. Epub 2015 Apr 24.
7
[Molecular international prognostic scoring system for myelodysplastic syndromes].[骨髓增生异常综合征的分子国际预后评分系统]
Rinsho Ketsueki. 2023;64(5):355-368. doi: 10.11406/rinketsu.64.355.
8
Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study.低危和中危-1型骨髓增生异常综合征患者使用新型预后指数的研究：一项基于人群的研究
Lancet Haematol. 2015 Jun;2(6):e260-6. doi: 10.1016/S2352-3026(15)00067-8. Epub 2015 May 20.
9
[Serum Erythropoietin as Prognostic Marker in Myelodysplastic Syndromes].[血清促红细胞生成素作为骨髓增生异常综合征的预后标志物]
Acta Med Port. 2015 Nov-Dec;28(6):720-5. Epub 2015 Dec 31.
10
Comparison of the prognostic predictive value of Molecular International Prognostic Scoring System and Revised International Prognostic Scoring System in patients undergoing allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms.分子国际预后评分系统与修订的国际预后评分系统对接受异基因造血干细胞移植治疗骨髓增生异常综合征患者的预后预测价值比较
Am J Hematol. 2023 Dec;98(12):E391-E394. doi: 10.1002/ajh.27099. Epub 2023 Sep 20.
引用本文的文献
1
A clinico-genomic prognostic model for primary myelodysplastic neoplasm in Asia.亚洲原发性骨髓增生异常综合征的临床基因组预后模型
Blood Cancer J. 2025 Jul 31;15(1):128. doi: 10.1038/s41408-025-01339-0.
2
IPSS-M outperforms IPSS-R in prognostic stratification and guides effective interventions for very High-Risk myelodysplastic syndrome patients undergoing allogeneic hematopoietic stem cell transplantation.国际预后评分系统-骨髓（IPSS-M）在预后分层方面优于国际预后评分系统-修订版（IPSS-R），并为接受异基因造血干细胞移植的极高危骨髓增生异常综合征患者指导有效的干预措施。
Discov Oncol. 2025 Jul 11;16(1):1315. doi: 10.1007/s12672-025-03155-1.
3
Advances and challenges in the treatment of myelodysplastic syndromes.骨髓增生异常综合征治疗的进展与挑战
Exp Hematol Oncol. 2025 Jun 18;14(1):87. doi: 10.1186/s40164-025-00678-9.
4
Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm.骨髓增生异常综合征/肿瘤的细胞遗传学克隆大小的临床相关性及预后影响
Blood Neoplasia. 2024 Dec 13;2(2):100062. doi: 10.1016/j.bneo.2024.100062. eCollection 2025 May.
5
Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.骨髓增生异常肿瘤的免疫监测：i4MDS联盟的建议
Hemasphere. 2024 May 15;8(5):e64. doi: 10.1002/hem3.64. eCollection 2024 May.
6
Clonal hematopoiesis-derived therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplant for lymphoid and non-lymphoid disorders.自体造血干细胞移植治疗淋巴和非淋巴系统疾病后，由克隆性造血衍生的治疗相关髓系肿瘤。
Leukemia. 2024 Jun;38(6):1266-1274. doi: 10.1038/s41375-024-02258-y. Epub 2024 Apr 29.
7
Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape.骨髓增生异常肿瘤（MDS）：当前和未来的治疗领域。
Curr Oncol. 2024 Apr 3;31(4):1971-1993. doi: 10.3390/curroncol31040148.
8
Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities.老年骨髓增生异常综合征的治疗：科学现状、挑战与机遇。
Curr Hematol Malig Rep. 2024 Jun;19(3):138-150. doi: 10.1007/s11899-024-00733-y. Epub 2024 Apr 18.
9
Kinome expression profiling improves risk stratification and therapeutic targeting in myelodysplastic syndromes.激酶组表达谱分析可改善骨髓增生异常综合征的风险分层和治疗靶向。
Blood Adv. 2024 May 28;8(10):2442-2454. doi: 10.1182/bloodadvances.2023011512.
10
Sustained remission after cord blood transplantation for breast cancer with lung metastases and myelodysplastic syndrome.乳腺癌伴肺转移和骨髓增生异常综合征患者经脐带血移植后获得持续缓解。
Int J Hematol. 2024 Jun;119(6):762-767. doi: 10.1007/s12185-024-03762-8. Epub 2024 Mar 25.
本文引用的文献
1
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.骨髓增生异常综合征的分子国际预后评分系统
NEJM Evid. 2022 Jul;1(7):EVIDoa2200008. doi: 10.1056/EVIDoa2200008. Epub 2022 Jun 12.
2
Have we reached a molecular era in myelodysplastic syndromes?我们是否已经进入骨髓增生异常综合征的分子时代？
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):418-427. doi: 10.1182/hematology.2021000276.
3
Myelodysplastic Syndromes.骨髓增生异常综合征
N Engl J Med. 2020 Oct 1;383(14):1358-1374. doi: 10.1056/NEJMra1904794.
4
Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes.机器学习表明体细胞突变在骨髓增生异常综合征中留下了不变的形态特征。
Blood. 2020 Nov 12;136(20):2249-2262. doi: 10.1182/blood.2020005488.
5
Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes.克隆性演变的不变模式决定了骨髓增生异常综合征的特定临床特征。
Nat Commun. 2019 Nov 26;10(1):5386. doi: 10.1038/s41467-019-13001-y.
6
Dynamics of clonal evolution in myelodysplastic syndromes.骨髓增生异常综合征的克隆进化动力学
Nat Genet. 2017 Feb;49(2):204-212. doi: 10.1038/ng.3742. Epub 2016 Dec 19.
7
Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.将分子数据纳入治疗骨髓增生异常综合征患者的修订国际预后评分系统。
Leukemia. 2016 Nov;30(11):2214-2220. doi: 10.1038/leu.2016.138. Epub 2016 May 20.
8
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.944例骨髓增生异常综合征患者的基因损伤图谱
Leukemia. 2014 Feb;28(2):241-7. doi: 10.1038/leu.2013.336. Epub 2013 Nov 13.
9
Revised international prognostic scoring system for myelodysplastic syndromes.修订版国际预后积分系统用于骨髓增生异常综合征。
Blood. 2012 Sep 20;120(12):2454-65. doi: 10.1182/blood-2012-03-420489. Epub 2012 Jun 27.
10
Clinical effect of point mutations in myelodysplastic syndromes.骨髓增生异常综合征点突变的临床疗效。
N Engl J Med. 2011 Jun 30;364(26):2496-506. doi: 10.1056/NEJMoa1013343.
Zotero 插件